A phase II Study of OSI-774 in unresectable hepatocellular carcinoma.

被引：0
|
作者：
Thomas, MB
Faria, S
Tamm, E
Rashid, A
Charnsangavej, C
Dancey, J
Abbruzzese, J
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6092S / 6092S
页数：1
相关论文
共 50 条
  • [21] Radiofrequency ablation for unresectable hepatocellular carcinoma.
    Ng, K
    Lam, CM
    Poon, R
    Ai, V
    Yuen, J
    Tso, WK
    Fan, ST
    HEPATOLOGY, 2002, 36 (04) : 684A - 684A
  • [22] A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma
    Zhu, AX
    Fuchs, CS
    Clark, JW
    Muzikansky, A
    Taylor, K
    Sheehan, S
    Tam, K
    Yung, E
    Kulke, MH
    Ryan, DP
    ONCOLOGIST, 2005, 10 (06): : 392 - 398
  • [23] A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma
    Ruff, P
    Chasen, MR
    Long, JEH
    van Rensburg, CEJ
    ANNALS OF ONCOLOGY, 1998, 9 (02) : 217 - 219
  • [24] Phase I trial of OSI-774 and CPT-11 in patients with advanced solid tumors
    Rao, RD
    Reid, JM
    Goetz, MP
    Furth, AF
    Mandrekar, SJ
    Adjei, AA
    Ames, MM
    Salgren, SL
    Erlichman, C
    Pitot, HC
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 208S - 208S
  • [25] Phase III trial of transarterial chemotherapy in patients with unresectable hepatocellular carcinoma.
    Rudolph, KL
    Kubicka, S
    Chavan, A
    Kirchhoff, TD
    Layer, G
    Gallkowski, U
    Schmoll, E
    Galanski, U
    Manns, MP
    HEPATOLOGY, 1997, 26 (04) : 1857 - 1857
  • [26] A phase II study of radiotherapy employing proton beam for hepatocellular carcinoma.
    Kawashima, M
    Furuse, J
    Nishio, T
    Konishi, M
    Ishii, H
    Kinoshita, T
    Nagase, M
    Nihei, K
    Ogino, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 319S - 319S
  • [27] A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma.
    Bi, Feng
    Qiu, Meng
    Chai, Xiaoli
    Niu, Junqi
    Ding, Yanhua
    Bai, Yuxian
    Wu, Lihua
    Shentu, Jianzhong
    Hao, Ping
    Chen, Jinfei
    Li, Qiu
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)
    Hirte, H.
    Oza, A.
    Swenerton, K.
    Ellard, S. L.
    Grimshaw, R.
    Fisher, B.
    Tsao, M.
    Seymour, L.
    GYNECOLOGIC ONCOLOGY, 2010, 118 (03) : 308 - 312
  • [29] Adjuvant chemotherapy and transplantation for unresectable hepatocellular carcinoma.
    Agarwal, K
    Smith, BC
    Jones, DEJ
    Hudson, M
    Bassendine, MF
    Mirza, D
    Manas, D
    HEPATOLOGY, 1997, 26 (04) : 1361 - 1361
  • [30] Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
    Chao, Y
    Chan, WK
    Birkhofer, MJ
    Hu, OYP
    Wang, SS
    Huang, YS
    Liu, M
    Whang-Peng, J
    Chi, KH
    Lui, WY
    Lee, SD
    BRITISH JOURNAL OF CANCER, 1998, 78 (01) : 34 - 39
12345